Filter by patients with: All

What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?

Category: Others

false

See also: Clinical Trial

NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.

See patients taking ALS Phase 3 Study Dexpramipexole (KNS-760704)

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Amyotrophic lateral sclerosis 38 96
Participate in clinical trial 17 21
Increase effect of another treatment 2 14
Arthritis pain in shoulder joints 1 0
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See all 71 patients that have used ALS Phase 3 Study Dexpramipexole (KNS-760704)

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 4
Moderate 4
Mild 28
None 66

Commonly reported side effects and conditions associated with ALS Phase 3 Study Dexpramipexole (KNS-760704)

Side effect Patients Percentage
Nausea 3
Heartburn 2
Insomnia 2
Neutropenia (low neutrophils) 2
Oily facial skin 2
Burning sensation in eyes 1

Show all 15 reported side effects

Why patients stopped taking ALS Phase 3 Study Dexpramipexole (KNS-760704)

Multiple reasons could be selected

Reason Patients Percentage
Course of treatment ended 12
Other 10
Did not seem to work 4
Side effects too severe 4
Doctor's advice 2
Personal research 1
See all 25 patients who've stopped using ALS Phase 3 Study Dexpramipexole (KNS-760704)

Duration

Stopped using ALS Phase 3 Study Dexpramipexole (KNS-760704)

Duration Patients Percentage
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 19
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 98
Usually 4
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 2
A little hard to take 13
Not at all hard to take 87
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 1
$50-99 1
$25-49 2
< $25 82
Not specified 16
Last updated:

6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)

Sort by: Most recent

Jan 16, 2013 (Started Aug 24, 2011)

  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg Daily
Cost: < $25 monthly

Nov 26, 2012 (Started Aug 24, 2011)

  • Effectiveness
    Major (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg Daily
Advice & Tips: Been rolled over to open-label for DEX. We hope to have a read-out soon (Dec/Jan) on results. I either have a really slow onset or this drug is really working... maybe both. While I've lost much strength in my right hand, all else is good for the last 2 years. My only negative was an early spike in Liver enzimines...
Cost: < $25 monthly
  • 0 helpful marks

Oct 11, 2012 (Started Jun 16, 2011)

  • Effectiveness
    Can't tell (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 300 mg Daily
Advice & Tips: This was a drug trial, I did'nt know if I had the placibo or the real drug. October 11,2012 the trial ended. They are giving me the real drug while they are analyzing the trial data.
  • 0 helpful marks

Oct 10, 2012 (Started Sep 10, 2011)

  • Effectiveness
    Can't tell (for Participate in clinical trial)
  • Effectiveness
    Can't tell (for amyotrophic lateral sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 2 Daily
  • 0 helpful marks
Last updated:
Showing 3 of 6 patient evaluations for ALS Phase 3 Study Dexpramipexole (KNS-760704)